Ester Ciociola
Overview
Explore the profile of Ester Ciociola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ciociola E, Dutta T, Sasidharan K, Kovooru L, Noto F, Pennisi G, et al.
Clin Mol Hepatol
. 2024 Dec;
PMID: 39716370
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global epidemic. MASLD has a strong genetic component, and a common missense variant (rs2642438) in the mitochondrial amidoxime-reducing component 1 (MARC1)...
2.
Pennisi G, Maurotti S, Ciociola E, Jamialahmadi O, Bertolazzi G, Mirarchi A, et al.
Arterioscler Thromb Vasc Biol
. 2024 Feb;
44(5):1086-1097.
PMID: 38385290
Background: ANGPTL3 (angiopoietin-like protein 3) is a circulating protein with a key role in maintaining lipoprotein homeostasis. A monoclonal antibody against ANGPTL3 is an approved and well-tolerated treatment to reduce...
3.
Dutta T, Sasidharan K, Ciociola E, Pennisi G, Noto F, Kovooru L, et al.
Liver Int
. 2024 Feb;
44(5):1219-1232.
PMID: 38375985
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global health concern with no effective and specific drug treatment available. The rs2642438 minor allele in mitochondrial amidoxime-reducing component 1 (MARC1)...
4.
Sasidharan K, Caddeo A, Jamialahmadi O, Noto F, Tomasi M, Malvestiti F, et al.
Cell Rep Med
. 2024 Jan;
5(1):101352.
PMID: 38232700
Steatotic liver disease (SLD) prevails as the most common chronic liver disease yet lack approved treatments due to incomplete understanding of pathogenesis. Recently, elevated hepatic and circulating interleukin 32 (IL-32)...
5.
Salomone F, Pipitone R, Longo M, Malvestiti F, Amorini A, Distefano A, et al.
J Hepatol
. 2024 Jan;
80(2):378.
PMID: 38182533
No abstract available.
6.
Salomone F, Pipitone R, Longo M, Malvestiti F, Amorini A, Distefano A, et al.
J Hepatol
. 2023 Oct;
80(1):10-19.
PMID: 37890719
Background & Aims: Sirtuin 5, encoded by the SIRT5 gene, is a NAD-dependent deacylase that modulates mitochondrial metabolic processes through post-translational modifications. In this study, we aimed to examine the...
7.
Tavaglione F, Jamialahmadi O, De Vincentis A, Qadri S, Mowlaei M, Mancina R, et al.
Clin Gastroenterol Hepatol
. 2022 Apr;
21(6):1523-1532.e1.
PMID: 35421583
Background & Aims: Noninvasive assessment of histological features of nonalcoholic fatty liver disease (NAFLD) has been an intensive research area over the last decade. Herein, we aimed to develop a...
8.
Baselli G, Jamialahmadi O, Pelusi S, Ciociola E, Malvestiti F, Saracino M, et al.
J Hepatol
. 2022 Apr;
77(3):596-606.
PMID: 35405176
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disorders and has a strong heritable component. The aim of this study was to identify new...
9.
Mancina R, Sasidharan K, Lindblom A, Wei Y, Ciociola E, Jamialahmadi O, et al.
Nat Metab
. 2022 Feb;
4(1):60-75.
PMID: 35102341
Fatty liver disease (FLD) is a growing health issue with burdening unmet clinical needs. FLD has a genetic component but, despite the common variants already identified, there is still a...
10.
Tavaglione F, De Vincentis A, Bruni V, Gallo I, Carotti S, Tuccinardi D, et al.
Liver Int
. 2021 Dec;
42(2):374-383.
PMID: 34890093
Background & Aims: The ultrasound-based controlled attenuation parameter (CAP) is a non-invasive tool widely validated for assessing liver steatosis across different etiologies. However, few studies, with liver biopsy available, have...